

# Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2020 and 2019

(Expressed in United States Dollars)

### INDEX TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

<u>Pa</u>	age
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS:	
Consolidated Statements of Financial Position	1
Consolidated Statements of Operations	2
Consolidated Statements of Changes in Stockholders' Equity	3
Consolidated Statements of Cash Flows	4
Notes to Condensed Interim Consolidated Financial Statements	5

# CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited)

		Sep	tember 30,	Dec	ember 31,
(in thousands)	Note		2020		2019
ASSETS					
Current assets:					
Cash and cash equivalents		\$	6,487	\$	1,344
Accounts Receivable—net of allowance for doubtful accounts of \$1,196 at					
September 30, 2020 and \$2,595 at December 31, 2019			4,167		6,890
Inventory	6		11,150		9,376
Biological assets	7		10,323		1,716
Prepaid expenses and other current assets	5		5,796		2,729
Total current assets		-	37,923		22,055
Long-term investments	10		652		397
Property and equipment, net	8		41,717		42,972
Goodwill	9		357		357
Other intangibles, net	9		567		1,153
Other assets			274		2,274
Total assets		\$	81,490	\$	69,208
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current liabilities:					
Accounts payable		\$	1,178	\$	7,127
Accrued payroll and benefits		Ą	985	Ş	531
	12		1,091		135
Notes payable, current portion	13				
Lease obligation, current portion	13		2,870		2,325
Other current liabilities		_	10,230	- 1	1,933
Total current liabilities	12		16,354 508		12,051 371
Notes payable	77.7				
Lease obligation	13		29,260		31,480
Convertible debentures	12		13,829		-
Other long-term liabilities		_	-		946
Total liabilities			59,951		44,848
STOCKHOLDERS' EQUITY					
Share capital			99,908		96,160
Accumulated deficit			(78,369)		(71,800)
Total stockholders' equity		-	21,539	- Av	24,360
Total liabilities and stockholders' equity		\$	81,490	\$	69,208

The interim consolidated financial statements were approved by the Board of Directors and were signed on its behalf by:

/s/ Mark Ainsworth
Mark Ainsworth, Chief Executive Officer

/s/ Steve Neil
Steve Neil, Chief Financial Officer

# CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Periods Ended September 30,			Three I	Mont	hs		Nine N	1ontl	ns
(in thousands except per share amounts)	Note		2020		2019		2020		2019
Net revenue		\$	14,131	\$	10,119	\$	33,467	\$	26,242
Cost of goods sold			8,269		17,738		29,652		31,004
Gross profit before biological asset adjustments			5,862		(7,618)		3,815		(4,762
Net effect of change in fair value of biological assets	7	_	(3,350)	177	(2,103)	-	(11,359)		(241
Gross profit			9,212		(5,515)		15,174		(4,522
Operating expenses									
General and administrative	18		2,559		8,787		8,575		16,754
Sales and marketing			1,274		2,606		3,684		6,016
Depreciation and amortization	8		1,044		985		2,806		2,444
Total operating expenses			4,878		12,378	-	15,066		25,214
Income/(Loss) from operations			4,334		(17,893)		108		(29,735)
Other income/(expense)									
Other income/(expense)			56		(104)		81		(17
Loss on termination of investment	4		(843)		5.		(4,367)		
Unrealized gain/(loss) on change in fair value of investment	10		(199)		(1,554)		192		(712
Gain/(Loss) on foreign currency			-		(21)		-		161
Interest expense	13		(838)		(525)		(2,414)		(2,066
Total other income/(expense)			(1,824)		(2,204)	- Po	(6,509)	8.	(2,633
Income/(Loss) before provision for income taxes			2,510		(20,097)		(6,400)		(32,369
Provision for income taxes	15		119		(459)		169		44
Net income/(loss)		\$	2,391	\$	(19,638)	\$	(6,569)	\$	(32,412
Net income/(loss) per share - basic	16	\$	0.07	\$	(0.61)	\$	(0.20)	\$	(1.01)
Net income/(loss) per share - diluted	16	\$	0.01	\$	(0.61)	\$	(0.20)	\$	(1.01
Weighted average shares outstanding - basic	16		33,398		32,228		33,048		32,199
	16		Section 1997		and the same of th				32,199
Weighted average shares outstanding - dasic Weighted average shares outstanding - diluted	2000.00		174,043		32,228		33,048		9200000

See accompanying notes to interim consolidated financial statements.

## CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)

					A	ttributable to Sha	reholders of the Pare	ent
			Subordinate	Super				
		Class A/B	Voting	Voting	Share	Accumulated	Non-Controlling	Stockholders
(in thousands)	Note	Shares	Shares	Shares	Capital	Deficit	Interest	Equity
Balance—December 31, 2018		28,497	-	-	\$ 54,333	\$ (20,201)	\$ -	\$ 34,132
Net loss				-	-	(32,412)	-	(32,412)
Adoption of lease accounting standard				-	-	(847)		(847)
Issuance of subordinate voting shares in exchange for Class A/B								
shares, net	3, 11	(28,497)	28,497			-		
Private placement in connection with reverse takeover, net	3, 11	-	3,433		36,762	4		36,762
Shares issued to acquiree in connection with reverse takeover	3, 11	-	130		1,513	*	-	1,513
Issuance of supervoting shares	3, 11	-		203	40	-		40
Issuances for acquisitions	4, 11	*	43	-	240		103	343
Exercise of options	11	-	125		127	3.40	-	127
Share-based compensation expense	11, 14		222		2,123	-		2,123
Balance—September 30, 2019		-	32,450	203	\$ 95,139	\$ (53,461)	\$ 103	\$ 41,782
Balance—December 31, 2019		-	32,844	203	\$ 96,160	\$ (71,800)	\$ -	\$ 24,360
Net loss		-	-	-	-	(6,569)	-	(6,569)
Issuance of stock warrants	11			-	1,556	2		1,556
Shares issued in connection with convertible debenture offering	12	-	250	(*)	62			62
Shares issued in connection with conversion of convertible								
debentures	12	-	54		11	-	-	11
Issuance of stock options associated with acquisitions	4			-	77	-		77
Exercise of warrants	11		107		30	-	5	30
Share-based compensation expense	11, 14		248		2,012			2,012
Balance—September 30, 2020			33,502	203	\$ 99,908	\$ (78,370)	\$ -	\$ 21,538

See accompanying notes to interim consolidated financial statements.

#### CONSOLIDATED STATEMENTS OF CASH FLOW

#### (Unaudited)

Periods Ended September 30,	_	Nine N	ionuis	
(in thousands)		2020	_	2019
CASH FLOW FROM OPERATING ACTIVITIES				
Net loss	\$	(6,569)	\$	(32,412
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization		3,044		2,901
Debt issuance cost amortization		352		-
Loss on termination of investment		4,367		-
Share-based compensation expense		2,012		2,123
Provision for doubtful accounts		1,000		230
Unrealized gain on change in fair value of investments		(192)		712
Changes in operating assets and liabilities:				
Accounts receivable		1,523		(7,307
Inventory		(1,774)		(1,206
Biological assets		(8,607)		(698
Prepaid expenses and other assets		(430)		(1,740
Accounts payable and accrued expenses		2,344		6,430
Other long-term liabilities		(90)		(304
Net cash used in operating activities		(3,019)		(31,270
CASH FLOW FROM INVESTING ACTIVITIES				
Purchases of property and equipment		(5,784)		(5,379
Net cash received from disposition of business interest		500		-
Investment in corporate interests		-		(1,500
Net cash used in investing activities		(5,284)		(6,879
CASH FLOW FROM FINANCING ACTIVITIES				
Principal payments on lease obligations		(1,795)		(1,082
Payments on notes payable		(3,990)		(83
Payments from lease obligations		120		-
Proceeds from notes payable		3,800		106
Proceeds from convertible notes, net of financing costs		15,219		
Issuance of subordinate voting shares associated with convertible notes offering		62		-
Proceeds from brokered private placement				40,150
Fees on public brokered private placement				(1,875
Proceeds from series B ofering				3,200
Proceeds from exercise of warrants		30		-
Proceeds from exercise of options				127
Issuance of subordinate voting shares				4
Net cash provided by financing activities	_	13,446	_	40,547
Change in cash and cash equivalents		5,143		2,398
Cash and cash equivalents—beginning of year		1,344		10,310
Cash, cash equivalents and restricted cash—end of period	\$	6,487	\$	12,708
con, con equitation and resultate con tend of period	<u> </u>	0,107	Ť	12,700
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION				
	\$	2,062	\$	1,247
Cash paid during the period for interest  Cash paid during the period for income taxes	\$	102	\$	1,247
Cash paid during the period for income taxes	3	102	Þ	-
OTHER NONCASH INVESTING AND FINANCING ACTIVITIES				
		500		
Purchase of property and equipment not yet paid for	\$	688	\$	-
Disposition of business interests	\$	500	\$	
Issuance of warrants	\$	1,556	\$	2,291
Shares issued for services in connection with convertible debenture offering	\$	62	\$	
Shares issued to acquiree in connection with reverse takeover	\$		\$	1,513
Issuance of supervoting shares	\$	•	\$	40
Acquisition of private entities	\$		\$	1,028
Issuance of subordinate voting shares in exchange for acquisition of private entity	\$	-	\$	240

See accompanying notes to interim consolidated financial statements.

#### NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

#### THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019

All amounts in these Notes are expressed in thousands of United States dollars ("\$" or "US\$"), unless otherwise indicated.

#### 1. NATURE OF OPERATIONS

On November 13, 2018, Indus Holding Company (a wholly owned subsidiary of Indus Holdings, Inc.) and Mezzotin Minerals Inc. ("Mezzotin") entered into a combination agreement whereby the parties agreed to combine their respective businesses, which would result in the reverse takeover of Mezzotin by the security holders of Indus. Mezzotin Minerals was originally incorporated under the Business Corporations Act (Ontario) on October 27, 2005 as Zoolander Corporation. On September 10, 2013, Zoolander changed its name to Mezzotin Minerals Inc. On April 26, 2019, the reverse takeover transaction concluded. In connection with the agreement, Mezzotin changed its name from Mezzotin Minerals Inc. to Indus Holdings, Inc. (the "Company", "Pubco", or "Indus"). Effective at the close of markets on April 29, 2019, the common shares of the Company ("Existing Mezzotin Shares") were delisted from the NEX board of the TSX Venture Exchange, and the subordinate voting shares of the Company commenced trading on the Canadian Stock Exchange effective at market open on April 30, 2019, under the new symbol "INDS".

Indus Holding Company ("IHC"), a Delaware corporation, was formed in 2014. Indus Holdings, Inc. became the indirect parent of IHC in connection with the reverse takeover transaction.

Indus Holdings, Inc., through its licensed subsidiaries, is a vertically integrated cannabis company that owns, manages and operates cultivation, extraction, distribution and manufacturing facilities in California.

The Company's corporate office and principal place of business is located at 19 Quail Run Circle, Salinas, California.

#### 2. SIGNIFICANT ACCOUNTING POLICIES

#### **Basis of Preparation**

The Company's consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). These condensed interim consolidated financial statements were approved and authorized for issue by the Board of Directors on November 9, 2020.

#### **Basis of Measurement**

These consolidated financial statements have been prepared on the going concern basis, under the historical cost convention, except for biological assets and certain financial instruments, which are measured at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets.

#### **Functional Currency**

The Company and its subsidiaries' functional currency, as determined by management, is the United States ("U.S.") dollar. These consolidated financial statements are presented in U.S. dollars.

Financial and other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.

#### **Classification of Expenses**

The expenses within the statements of operations are presented by function. Refer to Note 18 for details of expenses by nature.

#### **Basis of Consolidation**

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of the subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases.

These consolidated financial statements include the accounts of the Company and its subsidiaries:

- Indus Holding Company, a Delaware corporation, wholly owned by Indus Holdings, Inc.
- Cypress Holding Company, a Delaware limited liability company, wholly owned by Indus Holding Company
- Cypress Manufacturing Company, a California corporation, wholly owned by Indus Holding Company
- Indus Nevada LLC, a Nevada limited liability corporation, wholly owned by Indus Holding Company
- Wellness Innovation Group Incorporated, a California corporation, wholly owned by Indus Holding Company

Intercompany balances, and any unrealized gains and losses or income and expenses arising from transactions with subsidiaries, are eliminated.

#### **Adoption of Accounting Policies**

The Company adopting the following accounting policy in the current fiscal year:

IFRIC 23 Uncertainty over income tax treatments - clarifies the application of recognition and measurement requirement in IAS 12, Income Taxes, when there is uncertainty over income tax treatments. It specifically addresses whether an entity considers each tax treatment independently or collectively, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit (tax loss), tax bases, unused tax credits and tax rates, and how an entity considers changes in facts and circumstances. IFRIC 23 is effective for the Company's current annual period retrospectively and the adoption did not have a significant impact on the Company's consolidated financial statements.

#### 3. REVERSE TAKEOVER AND PRIVATE PLACEMENT

#### **Reverse Takeover**

As discussed in Note 1, on November 13, 2018, Indus Holding Company ("IHC"), a wholly owned subsidiary of Indus Holdings, Inc., and Mezzotin Minerals Inc. ("Mezzotin") entered into a combination agreement whereby the parties agreed to combine their respective businesses, which would result in the reverse takeover of Mezzotin by the security holders of Indus. On March 29, 2019, IHC and Mezzotin signed the Definitive Agreement subject to regulatory approval and on April 26, 2019 concluded the transaction. In connection with the agreement, Mezzotin changed its name from Mezzotin Minerals Inc. to Indus Holdings, Inc. Effective at the close of markets on April 29, 2019, the common shares of the Company ("Existing Mezzotin Shares") were delisted from the NEX board of the TSX Venture Exchange, and the subordinate voting shares of the Company ("Subordinate Voting Shares") commenced trading on the Canadian Securities Exchange effective at market open on April 30, 2019, under the new symbol "INDS".

Pursuant to the Transaction, the Existing Mezzotin Shares were redesignated as a new class of Subordinate Voting Shares on the basis of one Subordinate Voting Shares for every 485.3 Existing Mezzotin Shares. In addition, Indus created a new class of voting common shares and a new class of non-voting redeemable common shares ("Convertible Shares") and the outstanding shares of Indus ("Indus Shares") were reclassified as Convertible Shares at a rate of one (1) Convertible Share for every one (1) Indus Share held. The Company also amended its articles in connection with the Transaction to (i) continue from the Province of Ontario to the Province of British Columbia; and (ii) change its name from Mezzotin Minerals Inc. to Indus Holdings, Inc.

In accordance with IFRS 3, the substance of the transaction was a reverse takeover of a non-operating company. The transaction does not constitute a business combination since Mezzotin does not meet the definition of a business under IFRS 3. As a result, the transaction is accounted for as an asset acquisition.

In consideration for the acquisition of Mezzotin, Indus is deemed to have issued 130 shares of Indus subordinate voting shares representing \$1,513 total value based on the concurrent financing subscription price of CAD\$15.65 (US\$11.60). The excess of the purchase price over net assets acquired was charged to the consolidated statements of operations as RTO expense. Mezzotin equity was eliminated.

There were no identifiable assets of Mezzotin on the date of acquisition. The acquisition costs have been allocated as follows:

(in thousands)	
CONSIDERATION	
Fair value of subordinate voting shares issued	\$ 1,513
Transaction costs	 191
Total consideration	1,704
ASSETS ACQUIRED	
Total identifiable net assets acquired	-
Listing expenses	1,704
Total purchase price	\$ 1,704

Under the Transaction: (i) non-U.S. shareholders of Indus (and such U.S. shareholders of Indus as elected to participate) then contributed their Convertible Shares to the Company in exchange for Subordinate Voting Shares at a rate of one (1) Subordinate Voting Share for every one (1) Convertible Share contributed, and on a going-forward basis, U.S. shareholders of Indus may from time to time elect to redeem their Convertible Shares in exchange for Subordinate Voting Shares at the same rate (or under certain circumstances for the cash value of such shares as provided in the share terms for the Convertible Shares); (ii) a designated founder of Indus subscribed for non-participating, super-voting shares of the Company carrying voting rights that, in the aggregate, represent approximately 85% of the voting rights of the Company upon completion of the Transaction on a fully diluted basis; (iii) all warrants of Indus (including compensation options issued to financial advisors) remained outstanding and will now entitle the holders thereof to acquire Convertible Shares on the same terms and conditions and on an economically equivalent basis; and (iv) all stock options of Indus outstanding under Indus' existing equity incentive plan were assumed by the Company and will now entitle the holders thereof to acquire Subordinate Voting Shares on the same terms and conditions and on an economically equivalent basis in lieu of securities of Indus.

#### **Private Placement**

In connection with the Transaction, Indus completed a private placement offering (the "Private Placement") through a special purpose finance company ("FinanceCo") on April 2, 2019, pursuant to which FinanceCo issued an aggregate of 3,436 subscription receipts ("Subscription Receipts") at a price of CDN\$15.65 per Subscription Receipt to raise aggregate gross proceeds of approximately US\$40 million. The gross proceeds of the Private Placement, less certain associated expenses, were deposited into escrow (the "Escrowed Proceeds") pending satisfaction of certain specified release conditions (the "Escrow Release Conditions"), all of which were satisfied immediately prior to the completion of the Transaction. As a result, the Escrowed Proceeds were released to FinanceCo prior to the closing of the Transaction, and each Subscription Receipt was automatically converted, for no additional consideration, into one common share of FinanceCo. Following satisfaction of the Escrow Release Conditions, in connection with the Transaction, the Company acquired all of the issued and outstanding FinanceCo shares pursuant to a three-cornered amalgamation, and the former holders thereof (including the former holders of FinanceCo Shares acquired upon conversion of the Subscription Receipts) each received one Subordinate Voting Share in exchange for each FinanceCo share held.

Also in connection with the Private Placement, FinanceCo issued an aggregate of 198 broker warrants to the agents under the offering as partial consideration for their services in connection with the Private

Placement, each of which was exercisable to acquire one FinanceCo share at an exercise price of CDN\$15.65 for a period of two (2) years from the satisfaction of the Escrow Release Conditions. Upon completion of the amalgamation, the Broker Warrants were exchanged for compensation options of the Company which are exercisable to acquire Subordinate Voting Shares in lieu of FinanceCo Shares, otherwise upon the same terms and conditions.

#### 4. ACQUISITIONS

#### **Completed Acquisitions**

During 2019, the Company completed the following acquisitions, and allocated the purchase price as follows:

Ollows.		(1)	The	(2) Humble		
(in thousands)	Kaiz	en Inc.	Flov	ver Co.	1	otal
CONSIDERATION			3):			
Contingent Payment	\$	50	\$	44	\$	94
Note Payable		200		65		265
Fair value of subordinate voting shares		62		55		117
Total consideration	\$	312	\$	164	\$	476
PURCHASE PRICE ALLOCATION						
Assets Acquired						
Inventories	\$	-	\$	6	\$	6
Intangible assets - brands and trademarks		104		80		184
Intangible assets - technology and know-how		208		78		286
Liabilities assumed						
Notes payable		-		-		-
Total identifiable net assets	P-1	312	1.0	164	17	476
Noncontrolling interest		-		-		-
Fair value of net assets acquired	\$	312	\$	164	\$	476

These acquisitions qualified as a business combination under IFRS 3 and the consideration has been allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. No goodwill was recognized. The purchases have been accounted for by the acquisition method, with the results included in the Company's net earnings from the date of acquisition.

The fair value of the assets acquired and the liabilities assumed were finalized in the quarter ended June 30, 2020.

The Company also incurred \$47 in transactional costs related to the above acquisitions which were recorded in general and administrative expenses in the Consolidated Statements of Operations.

#### • Kaizen Inc.

On May 1, 2019, the Company acquired all of the assets, global rights and business interests of Kaizen Inc. for a purchase price of \$556 that will be paid as and if financial performance targets are met during the period beginning on May 1, 2019 and ending on April 30, 2023. Kaizen is a premium brand offering a full spectrum of cannabis concentrates. Effective July 15, 2020 the asset purchase agreement was modified, eliminating payments associated with meeting financial performance targets in exchange for the issuance of 225,000 options to purchase Subordinate Voting Shares and a note payable of \$200, with payments over two years. Had the modifications been reflected as of the date of acquisition, net assets would have decreased \$223 at December 31, 2019 and net loss in 2019 would have been reduced by \$21.

#### • The Humble Flower Co.

On April 18, 2019, the Company acquired all of the assets, global rights and business interests associated with the brand Humble Flower Co. for a purchase price of \$472 that will be paid as and if financial performance targets are met during the period beginning on April 19, 2019 and ending on April 18, 2023. The acquisition marks the Company's expansion into cannabis-infused topical creams, balms, and oils. Effective June 1, 2020 the asset purchase agreement was modified, eliminating payments associated with meeting financial performance targets in exchange for the issuance of 225,000 options to purchase Subordinate Voting Shares and a note payable of \$65, with payments commencing on January 1, 2021 for 24 months. Had the modifications been reflected as of the date of acquisition, net assets would have decreased \$308 at December 31, 2019 and net loss in 2019 would have been reduced by \$34.

#### Shredibles LLC

On June 12, 2019, the Company completed the acquisition of 70% of the outstanding capital stock of Shredibles LLC ("Shredibles"), a manufacturer of CBD infused health products, from its shareholders. In February 2020, the Company determined that Shredibles was not a strategic fit for the Company and reached an agreement with the Shredibles co-founders to nullify the investment. The termination has been reflected as being effective as of December 31, 2019 in the consolidated financial statements. The operations of Shredibles, and the termination of the agreement, did not have a material impact on the results of operations of the Company in 2019.

#### **Terminated Acquisition**

On May 14, 2019, the Company entered into a definitive agreement to acquire the assets of W The Brand ("W Vapes"), a manufacturer and distributor in Nevada and Oregon of cannabis concentrates, cartridges and disposable pens, in a cash and stock transaction. Under the terms of the agreement, the purchase consideration to W Vapes shareholders consisted of \$10 million in cash and \$10 million in Subordinate Voting Shares (based on a deemed value of CDN\$15.65 per share). In November 2019, the definitive agreement was amended whereby the Company advanced \$2 million in non-recourse funds to the seller in exchange for release of \$10 million of cash held in escrow related to the acquisition and in December 2019, the Company purchased the Las Vegas, Nevada facility for \$4.1 million.

On July 17, 2020, the Company announced the termination of the definitive agreement with W Vapes and is no longer obligated to acquire the assets of W Vapes. The termination of the agreement coincided with an asset acquisition announcement between W Vapes and Planet 13 Holdings Inc. ("Planet 13"). Additionally, the Company sold the Las Vegas facility to certain affiliates of Planet 13 for a cash payment of approximately \$500, and an additional cash payment of approximately \$2.8 million upon regulatory approval of the W Vapes and Planet 13 transaction, and in the third quarter the Company finalized a note payable of \$843 to the owners of W Vapes, payable coinciding with the receipt of the \$2.8 million payment from the facility sale. As a result, the Company has reflected a \$4.4 million loss in its consolidated financial statements.

The Company incurred \$251 in transactional costs related to the above acquisition for the year ended December 31, 2019, which were recorded in general and administrative expenses in the Consolidated Statements of Operations.

#### 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets were comprised of the following items:

	September	30,	Dece	ember 31,
(in thousands)	2020			2019
Deposits	\$	537	\$	542
Insurance		859		854
Supplier advances		654		742
Nevada building sale proceeds	2,	,800		-
Other		946		591
Total Prepaid Expenses and Other Current Assets	\$ 5,	796	\$	2,729

#### 6. INVENTORY

Inventory was comprised of the following items:

Nork in process Finished goods	September 30, 2020	ember 31, 2019
Raw materials	\$ 7,850	\$ 6,603
Work in process	32	34
Finished goods	3,268	2,739
Total Inventory	\$ 11,150	\$ 9,376

#### 7. BIOLOGICAL ASSETS

The Company's biological assets consists of cannabis plants. A reconciliation of the beginning and ending balances of biological assets for the nine months ended September 30, 2020 and the year ended December 31, 2019 are as follows:

	Sept	ember 30,	Dece	ember 31,	
		2020	2019		
Beginning balance	\$	1,716	\$	576	
Net change in fair value less costs to sell due to biological transformation		20,104		7,728	
Transferred to inventory upon harvest		(11,497)	_	(6,588)	
Ending balance	\$	10,323	\$	1,716	

The Company cultivates its plants within greenhouses that utilize natural light and those that use supplemental lighting. On average the full harvest growing cycle for natural light is 18 weeks and for supplemental lighting is 11 weeks. Commencing in the quarter ended March 31, 2020, supplemental lighting is being used for all harvests.

The valuation of biological assets is based on a market approach where fair value at the point of harvest is estimated based on selling prices less the costs to sell at harvest. For in process biological assets, the fair value at point of harvest is adjusted based on the stage of growth. The significant estimates and inputs used to assess the fair value of biological assets include the following assumptions:

- The selling price, which is based on the average market price in California where the Company operated during the nine months ended September 30, 2020 and the year ended December 31, 2019;
- The cost to complete the cannabis production process post-harvest and the cost to sell based on the Company's historical results;
- The average number of weeks in the growing cycle based on the Company's historical results;
- The stage of plant growth; and
- Expected yields from each cannabis plant based on the Company's historical results.

These inputs are level 3 on the fair value hierarchy, and are subject to volatility and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.

The Company has quantified the sensitivity of the inputs in relation to biological assets as of September 30, 2020 and December 31, 2019.

- Selling price per pound a decrease in the selling price per pound by 5% would result in the biological asset value decreasing by approximately \$718 at September 30, 2020 and \$72 at December 31, 2019.
- Estimated yield per plant a decrease in the yield per plant of 5% would result in the biological asset value decreasing by approximately \$516 at September 30, 2020 and \$27 at December 31, 2019.

As of September 30, 2020, on average, the biological assets were 62.0% complete as to the next expected harvest date, and it is expected that the Company's biological assets will ultimately yield approximately 13,251 pounds of cannabis and cannabis biomass.

#### 8. PROPERTY AND EQUIPMENT

A reconciliation of the beginning and ending balances of property and equipment and accumulated depreciation during the nine-month period ended September 30, 2020 is as follows:

(in thousands)	7.5	nd and uildings	1435	asehold ovements	22070	niture ixtures	Eq	uipment	Ve	hicles		struction Process	Right of e Assets	 Total
Costs														
Balance—December 31, 2019	\$	4,098	\$	4,275	\$	49	\$	1,100	\$	813	\$	2,533	\$ 34,114	\$ 46,982
Additions		8		1,937		1		84		39		3,602	106	5,777
Disposals/Transfers		(4,106)		3,410		-		21		-	,	(3,431)		(4,106)
Balance—September 30, 2020	\$		\$	9,622	\$	50	\$	1,205	\$	852	\$	2,704	\$ 34,220	\$ 48,653
Accumulated Depreciation														
Balance—December 31, 2019	\$	(8)	\$	(422)	\$	(46)	\$	(261)	\$	(249)	\$	-	\$ (3,025)	\$ (4,011)
Depreciation		(57)		(139)		(1)		(124)		(121)			(2,548)	(2,990)
Disposals		65												65
Balance—September 30, 2020	\$		\$	(561)	\$	(47)	\$	(385)	\$	(370)	\$		\$ (5,573)	\$ (6,936)
Net Book Value														
December 31, 2019	\$	4,090	\$	3,853	\$	3	\$	839	\$	565	\$	2,533	\$ 31,089	\$ 42,972
Balance—September 30, 2020	\$		\$	9,061	\$	3	\$	820	\$	482	\$	2,704	\$ 28,647	\$ 41,717

Construction in progress represent assets under construction related to cultivation, manufacturing, and distribution facilities not yet completed or otherwise not placed in service.

Depreciation expense of \$1,047 and \$3,021 were recorded for the three and nine months ended September 30, 2020, respectively, of which \$13 and \$238, respectively, were included in cost of goods sold. Depreciation expense of \$1,192 and \$2,902 were recorded for the three and nine months ended September 30, 2019, respectively, of which \$207 and \$458, respectively, were included in cost of goods sold.

#### 9. GOODWILL AND INTANGIBLE ASSETS

#### Goodwill

A reconciliation of the beginning and ending balances of goodwill during the nine months ended September 30, 2020 is as follows:

\$ 357
-
-
 -
\$ 357
\$

The Company evaluates goodwill for impairment annually during the fiscal third quarter and when an event occurs, or circumstances change such that it is reasonably possible that impairment may exist. The Company accounts for goodwill and evaluates its goodwill balances and tests them for impairment in accordance with related accounting standards. The Company performed its annual impairment assessment in its third quarter of fiscal 2020, and its analysis indicated that the Company had no impairment of goodwill.

#### **Other Intangible Assets**

A reconciliation of the beginning and ending balances of intangible assets and accumulated amortization during the nine months ended September 30, 2020 is as follows:

Indefinite

			D	efinite Life	Intang	ibles				Life ngibles	
	Bra	anding	Cus	tomer	Tech	nology/	0	ther	Bra	ands &	
(in thousands)	R	ights	Relat	ionships	Kno	wHow	Inta	ngibles	Trad	enames	 Total
Costs											
Balance—December 31, 2019	\$	250	\$	40	\$	421	\$	40	\$	522	\$ 1,273
Purchase price adjustment		-	92	(40)		(213)	72	(40)		(293)	(586)
Balance—September 30, 2020	\$	250	\$	:: <u>*</u>	\$	208	\$	12	\$	229	\$ 687
Accumulated Amortization											
Balance—December 31, 2019	\$	(76)	\$	(8)	\$	(28)	\$	(8)	\$	-	\$ (120)
Purchase price adjustment		-		12		30		12		-	54
Amortization		(13)	-	(4)	-	(33)	311	(4)			 (54)
Balance—September 30, 2020	\$	(89)	\$	(-)	\$	(31)	\$		\$	-	\$ (120)
Net Book Value											
December 31, 2019	\$	174	\$	32	\$	393	\$	32	\$	522	\$ 1,153
September 30, 2020	\$	161	\$	-	\$	177	\$	-	\$	229	\$ 567

Intangible assets with finite lives are amortized over their estimated useful lives. Amortization periods of assets with finite lives are based on management's estimates at the date of acquisition. The Company recorded amortization expense of \$54 for the nine months ended September 30, 2020. As described in Note 4, during the quarter ended June 30, 2020, the Company modified certain purchase agreements resulting in adjustments to certain intangible assets.

The Company estimates that amortization expense for our existing other intangible assets will be approximately \$40 annually for each of the next five fiscal years. Actual amortization expense to be reported in future periods could differ from these estimates as a result of new intangible asset acquisitions, changes in useful lives or other relevant factors or changes.

#### **10. INVESTMENTS**

The Company from time to time acquires interest in various corporate entities for investment purposes. The investments are measured at fair value to profit or loss ("FVTPL") and are classified as Level 3 in the fair value hierarchy in accordance with IFRS 9 - Financial Instruments.

In March 2019, the Company entered into a strategic partnership with Orchid Ventures ("Orchid"). Under the terms of the partnership, Indus secured the exclusive sales and distribution rights to Orchid's line of Orchid Essentials vape devices in California. In addition, Indus acquired an interest in Orchid for \$1,500 during Orchid's RTO financing round. The Company's investment in Orchid is classified as Level 1 in the fair value hierarchy. The Company adjusted its carrying value based on the share price at the balance sheet date, recognizing an unrecognized gain/(loss) of (\$107) and \$85 in its Statements of Operations for the three and nine months ended September 30, 2020.

In October 2018, the Company contributed 77,689 shares of Series B preferred shares at a value of \$350, to a joint venture arrangement with Dametra LLC, in which each partner has 50% ownership. Under the arrangement Indus is the exclusive manufacturer and distributor of Canna Stripe branded products in the state of California. The investment was accounted for in accordance with IFRS 11. The Company's investment in Dametra is classified as Level 3 in the fair value hierarchy. Due to the highly competitive gummy product market and the limited success to the launching of the Canna Stripe brand, the Company determined that the carrying value of the investment was nominal and a (\$350) loss was recognized in the fourth quarter of 2019.

In the fourth quarter of 2018, the Company acquired an interest for \$148 in a long-standing business partner who creates and markets cannabis brands. The business partner was acquired by Green Thumb Industries in February 2019. The Company's investment in Green Thumb Industries is classified as Level 1 in the fair value hierarchy. The Company sold approximately 65.7% of its interests in 2019, recognizing a realized gain of \$476. The Company adjusts its carrying value based on the share price at the balance sheet date, recognizing an unrealized gain/(loss) of (\$92) and \$107 in its Statement of Operations for the three and nine months ended September 30, 2020.

The Company issued 325 shares of common stock valued at \$650 in exchange for shares in Haight & Ashbury Corp, a technology company developing an e-commerce platform. Due to the lack of extensive roll out of the e-commerce platform with brands and dispensaries within California and in other states, the Company determined that the carrying value of the investment was nominal. As such, a (\$650) loss was recognized in the fourth quarter of 2019.

#### 11. SHAREHOLDERS' EQUITY

#### **Shares Outstanding**

The table below details the change in Company shares outstanding by class during the nine-month period ended September 30, 2020:

(in thousands)	Subordinate Voting Shares	Super Voting Shares
Balance—December 31, 2019	32,844	203
Shares issued in connection with convertible debenture offering	250	-
Shares issued in connection with exercise of warrants	107	(4)
Shares issued in connection with conversion of convertible debentures	54	-
Issuance of vested restricted stock units	248	
Balance—September 30, 2020	33,502	203

As discussed in Note 3, in consideration for the acquisition of Mezzotin in connection with the reverse takeover, Indus issued 130 shares of Indus subordinate voting shares representing \$1,513 total value based on the concurrent financing subscription price of CAD\$15.65 (US\$11.60). The excess of the purchase price over net assets acquired was charged to the consolidated statements of operations as RTO expense in general and administrative expenses.

#### **Warrants**

A reconciliation of the beginning and ending balance of warrants outstanding is as follows:

#### (in thousands)

Polymer Programme 21 2010	2.700
Balance—December 31, 2019	2,769
Warrants issued in conjunction with convvertible debenture offering	80,379
Warrants converted into subordinate voting shares	(107)
Balance—September 30, 2020	83,041

**12. DEBT** 

Debt at September 30, 2020 and December 31, 2019 was comprised of the following:

(in thousands)	September 30, 2020		December 31, 2019	
Current portion of long-term debt				
Vehicle loans <sup>(1)</sup>	\$ 174	\$	135	
Note payable <sup>(3)</sup>	917		-	
Total short-term debt	1,091		135	
Long-term debt, net				
Vehicle loans <sup>(1)</sup>	254		233	
Note payable <sup>(2)</sup>	113		138	
Note payable <sup>(3)</sup>	141		-	
Convertible debenture <sup>(4)</sup>	13,829	20	-	
Total long-term debt	14,337		371	
Total Indebtedness	\$ 15,428	\$	506	

<sup>(1)</sup> Primarily fixed term loans on transportation vehicles.

Stated maturities of debt obligations are as follows:

	September 30,
(in thousands)	2020
2020	\$ 60
2021	1,122
2022	228
2023	16,114
2024	21
2025 and thereafter	6
Total debt obligations	\$ 17,551

On April 13, 2020, the Company entered into a \$15.1 million senior secured convertible debenture and warrant purchase agreement. In late April and May 2020 an additional \$1 million was funded to bring the total convertible debenture amount to \$16.1 million. The convertible debentures are convertible, at a conversion price of \$0.20 per share, into an aggregate of 80.4 million subordinate voting shares of the Company, and the Company issued warrants to purchase an aggregate of 80.4 million subordinate voting shares at an exercise price of \$.28 per share. The financing yielded the Company approximately \$11.5 million after repayment of \$3.8 million in bridge financing received during the first quarter, plus accrued interest thereon, and transaction related expenses of approximately \$600. The debentures bear interest at 5.5% per annum and will mature in October 2023, and the warrants expire in October 2023. During the

<sup>(2)</sup> Note payable in connection with Acme acquisition to be paid as and if financial performance targets are met over the earnout period.

<sup>(3)</sup> Note payable in connection with Humble Flower and Kaizen acquisitions and termination of the W Vapes acquisition.

<sup>(4)</sup> Net of deferred financing costs of \$2,236.

three months ended September 30, 2020, \$11 of convertible debentures were converted into 54 Subordinate Voting Shares.

#### 13. LEASES

The Company adopted IFRS 16 - *Leases* effective January 1, 2019 using the modified retrospective adoption method which allowed it to initially apply the new standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit. In connection with the adoption of the new lease pronouncement, the Company recorded a charge to accumulated deficit of \$847.

A reconciliation of lease obligations for the nine-month period ended September 30, 2020 was comprised of the following:

(in thousands)	Septem	ber 30, 2020
Lease Liability		
December 31, 2019	\$	33,805
Additions		120
Lease principal payments		(1,795)
September 30, 2020	\$	32,130
Lease obligation, current portion	\$	2,870
Lease obligation, long-term portion	\$	29,260

All extension options that are reasonably certain to be exercised have been included in the measurement of lease obligations. The Company reassesses the likelihood of extension option exercise if there is a significant event or change in circumstances within its control.

The components of lease expense for the nine-month period ended September 30, 2020 was as follows:

#### Periods Ended September 30, 2020

(in thousands)		e Months	Nine Months		
Amortization of leased assets <sup>(1)</sup>	\$	839	\$	1,631	
Interest on lease liabilities <sup>(2)</sup>		491		964	
Total	\$	1,330	\$	2,595	
Included in cost of goods sold and general and administrative in the consolidated statement of operations.					

<sup>(2)</sup> Included in interest expense in the consolidated statement of operations.

The key assumptions used in accounting for our leases as of September 30, 2020 were a weighted average remaining lease term of 10.6 years and a weighted average discount rate of 6.0%.

The future lease payments with initial remaining terms in excess of one year as of September 30, 2020 were as follows:

(in thousands)	September 30, 2020
Less than 1 year	\$ 2,262
1 - 3 years	11,439
4 - 5 Years	5,175
Greater than 5 years	13,254
Total	\$ 32,130

#### 14. SHARE-BASED COMPENSATION

During 2019 the Company's Board of Directors adopted the 2019 Stock and Incentive Plan (the "Plan"), which was amended in April 2020. The Plan permits the issuance of stock options, stock appreciation rights, stock awards, share units, performance shares, performance units and other stock-based awards up to 8.2 million in total. The Plan provides for the grant of options as either non-statutory stock options or incentive stock options and restricted stock units to employees, officers, directors, and consultants of the Company to attract and retain persons of ability to perform services for the Company and to reward such individuals who contribute to the achievement by the Company of its economic objectives. The awards granted generally vest in 25% increments over a four-year period and option awards expire 6 years from grant date.

The Plan is administered by the Board or a committee appointed by the Board, which determines the persons to whom the awards will be granted, the type of awards to be granted, the number of awards to be granted, and the specific terms of each grant, including the vesting thereof, subject to the provisions of the Plan.

During the nine months ended September 30, 2020, the Company granted shares to certain employees as compensation for services. These shares were accounted for in accordance with IFRS 2 - *Share-based Payments*. The Company amortizes awards over the service period and until awards are fully vested.

For the three and nine months ended September 30, 2020 and 2019, share-based compensation expense recorded to the Company's consolidated statements of operations were:

Periods Ended September 30,	Three Months				Nine Months			
(in thousands)	2020		2019		2020		2019	
Cost of goods sold	\$		\$	-	\$	-	\$	-
General and administrative expense		187		1,613		2,012	63	2,123
Total share based compensation	\$	187	\$	1,613	\$	2,012	\$	2,123

The following table summarizes the status of grants and unvested awards as of September 30, 2020 and December 31, 2019 and for the nine-month period ended September 30, 2020:

			Weighted-Average		
	Stock	Weighted-Average	Remaining	Ag	gregate
(in thousands except per share amounts)	Options	Exercise Price	Contractual Life	Intri	nsic Value
Outstanding—December 31, 2019	1,543	\$2.53	4.3	\$	
Granted	4,490	0.50			
Exercised	4,490	-			
Cancelled	(334)	2.47	22	-80	
Outstanding—September 30, 2020	5,699	\$0.86	3.9	\$	2,761
Exercisable—September 30, 2020	581	\$3.31	2.3	\$	2
Vested and expected to vest—September 30, 2020	5,699	\$0.86	3.9	\$	2,761

The fair value of the stock options granted was determined using the Black-Scholes option-pricing model with the following weighted average assumptions at the time of grant.

Periods Ended September 30, 2020	Three Months	Nine Months
Expected volatility	50.0%	50.0%
Dividend yield	0%	0%
Risk-free interest rate	0.4%	0.5%
Expected term in years	6.0	6.0

Restricted Stock Units (RSU) —On June 7, 2019, in connection with the reverse takeover discussed in Note 3, 729 RSUs were awarded in total to executive employees and independent board members, and 235 RSUs were awarded to other key employees under the Plan. The RSUs vested in 25% increments over a period of ten months. In the quarter ended March 31, 2020, 145 RSUs under the Plan were awarded to executive employees and independent board members vesting on December 31, 2020, and 68 RSUs under the Plan to other employees, vesting periodically in 2020. In the quarter ended June 30, 2020, 450 RSU's were awarded to an independent advisor of the Company, vesting in October 2021. In the quarter ended September 30, 2020, 67 RSUs were awarded to independent board members vesting on December 31, 2020. The fair value for RSUs is based on the Company's share price on the date of the grant. The Company recorded \$109 and \$1,722 as compensation expense and nil and 248 net shares vested during the three and nine months ended September 30, 2020, respectively, in connection with these awards. At September 30, 2020 there were 729 restricted stock units outstanding.

#### **15. INCOME TAXES**

The provision for income tax expense for the three and nine months ended September 30, 2020 were \$119 and \$169, respectively, representing an effective tax rate of 3.5% and (3.0)%, respectively, compared to income tax benefit of \$459 in the three months ended September 30, 2019 and income tax expense of \$44 in the nine months ended September 30, 2019, representing an effective tax rate of 2.3% and (0.1)%, respectively.

#### 16. EARNINGS/(LOSS) PER SHARE

Net earnings/loss per share represents the net earnings/loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis.

Periods Ended September 30,	Three	Months	Nine Months				
(in thousands except per share amounts)	2020	2019	2020	2019			
Net earnings (loss) attributable to Indus Holdings, Inc.	\$ 2,391	\$ (19,638)	\$ (6,569)	\$ (32,412)			
Basic							
Weighted average subordinate voting shares <sup>(1)</sup>	33,398	32,228	33,048	32,199			
Basic earnings (loss) per share attributable to Indus Holdings, Inc.	\$ 0.07	\$ (0.61)	\$ (0.20)	\$ (1.01)			
Diluted							
Weighted average subordinate voting shares <sup>(1)</sup>	33,398	32,228	33,048	32,199			
Effects of Potential Dilutive Shares							
Options	2,192	-	-				
Warrants	57,395	-	-	-			
Convertible debentures	80,361	· <del>-</del>	•	-			
Restricted stock units	697	-					
Diluted weighted average subordinate voting shares	174,043	32,228	33,048	32,199			
Diluted earnings (loss) per share attributable to Indus Holdings, Inc.	\$ 0.01	\$ (0.61)	\$ (0.20)	\$ (1.01)			

<sup>(1)</sup> On an as converted basis.

As the Company is in a loss position for the nine months ended September 30, 2020 and 2019 and for the three months ended September 30, 2019, the inclusion of options, warrants, convertible debentures and restricted stock units in the calculation of diluted earnings per share would be anti-dilutive, and accordingly, were excluded from the diluted loss per share calculation.

#### 17. COMMITMENTS AND CONTINGENCIES

#### **Commitments**

The Company's commitment with W Vapes to acquire assets in Nevada and Oregon was terminated on July 17, 2020. See Note 4.

#### **Contingencies**

The Company's operations are subject to a variety of local and state regulation. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulation as of September 30, 2020, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future.

#### **Litigation and Claims**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 30, 2020, there were no pending or threatened lawsuits

that could reasonably be expected to have a material effect on the results of the Company's operations. There are also no proceedings in which any of the Company's directors, officers or affiliates are an adverse party or have a material interest adverse to the Company's interest. The Company is the respondent in an arbitration action filed against it following the termination by the Company of its agreement with a third party distribution technology services provider. The Company believes it has meritorious defenses and the action is without merit, and while there can be no assurance as to the outcome of any contested proceeding, the Company believes that the resolution of this matter will not have a material adverse effect on the Company or its operating results.

#### 18. GENERAL AND ADMINISTRATIVE EXPENSES

For the three and nine months ended September 30, 2020, and 2019, general and administrative expenses were comprised of:

Periods Ended September 30,	Three Months				Nine Months			
(in thousands) Salaries and benefits	2020		2019		2020		2019	
	\$	1,175	\$	3,002	\$	3,151	\$	6,326
Professional fees		444		575		1,294		1,110
Share-based compensation		187		1,613		2,012		2,123
Administrative		753		3,097		2,118		5,084
Transaction and other special charges (1)	93	-	12	500	100	-	ay.	2,111
Total general and administrative expenses	\$	2,559	\$	8,787	\$	8,575	\$	16,754

<sup>(1)</sup> Includes charges associated with acquisitions and the Company's reverse takeover.

#### 19. RELATED-PARTY TRANSACTIONS

Transactions with related parties are entered into in the normal course of business and are measured at the amount established and agreed to by the parties.

Indus receives certain administrative, operational and consulting services through a Management Services Agreement with Edibles Management, LLC ("EM"). EM is a limited liability company owned by the cofounders of Indus and was formed to provide Indus with certain administrative functions comprising: cultivation, distribution, and production operations support; general administration; corporate development; human resources; finance and accounting; marketing; sales; legal and compliance. The agreement provides for the dollar-for-dollar reimbursement of expenses incurred by EM in performance of its services. Amounts paid to EM for the three months ended September 30, 2020 and 2019 were \$3,021 and \$4,982, respectively, and for the nine months ended September 30, 2020 and 2019 were \$8,062 and \$11,578, respectively.

In April 2015, Indus entered into a services agreement with Olympic Management Group ("OMG"), for advisory and technology support services, including the access and use of software licensed to OMG to perform certain data processing and enterprise resource planning (ERP) operational services. OMG is owned by one of the Company's co-founders. The agreement provides for the dollar-for-dollar reimbursement of expenses incurred by OMG in performance of its services. Amounts paid to OMG for the three months ended September 30, 2020 and 2019 were nil in both periods, and for the nine months ended September 30, 2020 and 2019 were \$5 and \$66, respectively.

#### 20. FINANCIAL RISK MANAGEMENT

The Company has exposure to the following risks from its use of financial instruments and other risks to which it is exposed and assess the impact and likelihood of those risks. These risks include: market, credit, liquidity, asset forfeiture, banking and interest rate risk.

#### **Credit Risk**

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The maximum credit exposure at September 30, 2020 and December 31, 2019 is the carrying amount of cash and cash equivalents and accounts receivable. All cash and cash equivalents are placed with U.S. and Canadian financial institutions.

The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk but has limited risk as a significant portion of its sales are transacted with cash.

#### **Liquidity Risk**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to settle obligations and liabilities when due.

In addition to the commitments outlined in Note 17, the Company has the following contractual obligations:

	Maturity:	Maturity: >1 Year			
(in thousands)	September 30, 2020	December 31, 2019	September 30, 2020	December 31, 2019	
Accounts payable and		N			
Other accrued liabilities	\$ 11,408	\$ 9,060	\$ -	\$ -	

#### **Market Risk**

Strategic and operational risks arise if the Company fails to carry out business operations and/or to raise sufficient equity and/or debt financing. These strategic opportunities or threats arise from a range of factors that might include changing economic and political circumstances and regulatory approvals and competitor actions. The risk is mitigated by consideration of other potential development opportunities and challenges which management may undertake.

#### **Interest Rate Risk**

Interest rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate as a result of changes in market interest rates. The Company's interest-bearing loans and borrowings are all at fixed interest rates; therefore, the Company is not exposed to interest rate risk on these financial liabilities. The Company considers interest rate risk to be immaterial.

#### **Price Risk**

Price risk is the risk of variability in fair value due to movements in equity or market prices. Cannabis is a developing market and likely subject to volatile and possibly declining prices year over year as a result of increased competition. Because adult-use cannabis is a newly commercialized and regulated industry in the State of California, historical price data is either not available or not predictive of future price levels. There may be downward pressure on the average price for cannabis. There can be no assurance that price volatility will be favorable to Indus or in line with expectations. Pricing will depend on general factors including, but not limited to, the number of licenses granted by the local and state governments, the supply such licensees are able to generate and consumer demand for cannabis. An adverse change in cannabis prices, or in investors' beliefs about trends in those prices, could have a material adverse outcome on the Company and its valuation.

#### **Asset Forfeiture Risk**

Because the cannabis industry remains illegal under U.S. federal law, any property owned by participants in the cannabis industry which are either used in the course of conducting such business, or are the proceeds of such business, could be subject to seizure by law enforcement and subsequent civil asset forfeiture. Even if the owner of the property were never charged with a crime, the property in question could still be seized and subject to an administrative proceeding by which, with minimal due process, it could be subject to forfeiture.

#### **Banking Risk**

Notwithstanding that a majority of states have legalized medical marijuana, there has been no change in U.S. federal banking laws related to the deposit and holding of funds derived from activities related to the marijuana industry. Given that U.S. federal law provides that the production and possession of cannabis is illegal, there is a strong argument that banks cannot accept for deposit funds from businesses involved with the marijuana industry. Consequently, businesses involved in the marijuana industry often have difficulty accessing the U.S. banking system and traditional financing sources. The inability to open bank accounts with certain institutions may make it difficult to operate the businesses of the Company, its subsidiaries and investee companies, and leaves their cash holdings vulnerable.

#### **21. SEGMENT INFORMATION**

The Company's operations are comprised of a single reporting operating segment engaged in the production and sale of cannabis products in the United States. As the operations comprise a single reporting segment, amounts disclosed in the financial statements also represent a single reporting segment.

#### **22. SUBSEQUENT EVENTS**

The Company has evaluated subsequent events through November 9, 2020, the date the financial statements were available to be issued.